Skip to main content
JEIL PHARMA HOLDINGS INC. logo

JEIL PHARMA HOLDINGS INC. — Investor Relations & Filings

Ticker · 002620 ISIN · KR7002620003 KO Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2026-05-18 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 002620

About JEIL PHARMA HOLDINGS INC.

https://www.jeilpharm.co.kr/english/

Jeil Pharma Holdings Inc., established in 1959, is a pharmaceutical company engaged in the development, manufacturing, and distribution of medical products. The company's portfolio includes finished pharmaceutical products, active pharmaceutical ingredients (APIs), incrementally modified drugs, and generic drugs. Key product categories include analgesic anti-inflammatories and broad-spectrum oral medications. The company is also focused on developing high-value products and aims to be a leading manufacturer of injection medicines.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서 (제 67 기 1분기)” covering the period 2026-01-01 to 2026-03-31 and contains full tables of contents including financial statements, notes, management discussion, auditor opinions, and detailed schedules. It is a comprehensive quarterly report (with corrected disclosures), not merely an announcement of its publication. Therefore it matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is a statutory quarterly report (‘분기보고서’) for the 67th fiscal year 1st quarter covering the period January 1, 2026 to March 31, 2026. It runs over 200k characters and contains full financial statements, notes, management discussion (II. 사업의 내용), summary financial information (III. 재무에 관한 사항), audit opinion (V. 회계감사인의 감사의견 등), and other required schedules. This is a complete interim/quarterly report, not merely an announcement or supplement. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It details the ownership percentages, changes in shareholdings, relationships between shareholders, and the purpose of holdings, including management influence. It includes specific dates, shareholder names, share counts, and changes in holdings. This type of document corresponds to notifications about changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document is lengthy (9557 characters) and contains detailed data, not just an announcement or a brief note, confirming it is the actual report of shareholding changes rather than a mere announcement. Therefore, the correct classification is MRQ with high confidence.
2026-04-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “정기주주총회결과” and contains the voting outcomes for each agenda item (approval of financial statements, election of directors, changes to articles, etc.) at the regular shareholders’ meeting. It reports the percentages of votes for and against, dividend resolutions, and appointment details. This matches the definition of a “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a Korean disclosure titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” detailing the appointment/reappointment of an outside (independent) director, including dates and term information. It is addressed to the Financial Services Commission/Korea Exchange and describes changes in board composition. This matches the Board/Management Information category (announcement of changes in the company’s board of directors).
2026-03-24 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for Jeil Pharma Holdings, covering the 66th fiscal year (2025). It contains detailed sections on company overview, business operations, financial statements (audited), management discussion and analysis, and governance. This structure matches the standard requirements for an Annual Report (10-K equivalent in the Korean market). FY 2025
2026-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.